Rimonabant Acomplia is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Its main avenue of effect is reduction in appetite. Obesity is now the most common nutritional disorder …

Buy Acomplia Rimonabant Online
Acomplia (Rimonabant) is is an oral prescription medication to treat obesity. It woks on the principle of blocking the CB-1 receptors situated in the Endo-cannabinoid system. Consumption of Acomplia primarily blocks the functioning of these …

OBESITY
When scientists at Sanofi-Aventis took on the challenge of developing a weight-loss drug, they chose an unusual approach. Instead of studying ways to curb the body’s natural desire to eat, they decided to home in on the very biological …

There are a large number of people who are obese. The magnitude of the situation becomes clear only when we are aware of the statistics. It is estimated that 70% of the diseases caused in the U.S. is due to …

Diet Pills: An Effective Approach to Lose Weight
A healthy and fit body is the ones identification for a successful lifestyle. In Today’s competitive world; everyone wants to have good looking personality and is getting conscious about his health and fitness. …

Rimonabant (Acomplia), discovered and developed by French pharmaceutical company Sanofi-Synthelabo, is a new drug thas has shown great promise in trials for the treatment of obesity and related metabolic risk factors. Rimonabant is already on the market in Europe, being …

Sanofi-Synthelabo, a French Pharmaceutical Company created Rimonabant (Acomplia and possibly Zimulti) which is a new drug treatment for obesity and possibly other ailments.

This diet pill was officially approved in Britain on June 28th 2006, which could lead the way to …

f you take the diet drug Acomplia, you can keep off lost pounds only if you keep taking it, researchers say.

And those who stay on the drug keep their smaller waist, lower blood-fat levels, and higher good cholesterol levels.

If you …

Tests of the new diet drug Acomplia show that users lost 10 percent or more of their body weight and kept that weight off for two years. The drug impedes the sensation of hunger by suppressing the part of the …

Lost in all the talk surrounding Sanofi-Sythelabo’s (NYSE: SNY) attempts to acquire Aventis (NYSE: AVE) is the fact that the company just released great phase 3 data on a pill that would help stop two of the nation’s biggest killers …